Moderna's mRNA Mpox Vaccine Shows Strong Protection in Animal Study, Stock Rises 1.44%

Sep 4, 2024, 03:03 PM

Moderna has reported encouraging results for its mRNA mpox vaccine in a recent animal study. The study, which compared the Moderna vaccine to the Jynneos vaccine in monkeys, found that the mRNA vaccine provided significantly stronger protection. Unvaccinated animals had a maximum of 1,448 lesions, Jynneos-vaccinated animals had a maximum of 607 lesions, while mRNA-immunized animals had a maximum of 54 lesions. These promising results come as mpox outbreaks continue to spread in Africa. A Phase 1/2 human trial for the Moderna mpox vaccine is already underway. Moderna's stock rose by 1.44% following the announcement.